Paper34944934
Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.
Mayayo-Peralta I and 13 others. Cancers (Basel), 2021. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Papers, record 34944934. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34944934
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 12011 | Cancer Research UK | United Kingdom | PubMed | |
| 91716401 | Dutch Research Council | Netherlands | PubMed | |
| Zwart | Oncode Institute | PubMed |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31823286 | Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells. | Breast Cancer | 2020 | https://conductscience.org/library/papers/31823286 | PubMed |
| 2 | 16929185 | Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. | Cell Cycle | 2006 | https://conductscience.org/library/papers/16929185 | PubMed |
| 3 | 29662238 | Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/29662238 | PubMed |
| 4 | 27020857 | Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. | Cancer Res | 2016 | https://conductscience.org/library/papers/27020857 | PubMed |
| 5 | 24942700 | Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. | Mol Cell Proteomics | 2014 | https://conductscience.org/library/papers/24942700 | PubMed |
| 6 | 30053671 | Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. | Eur J Cancer | 2018 | https://conductscience.org/library/papers/30053671 | PubMed |
| 7 | 32482536 | Senescent Cells in Cancer Therapy: Friends or Foes? | Trends Cancer | 2020 | https://conductscience.org/library/papers/32482536 | PubMed |
| 8 | 29935900 | Mechanisms of therapeutic CDK4/6 inhibition in breast cancer. | Semin Oncol | 2017 | https://conductscience.org/library/papers/29935900 | PubMed |
| 9 | 28344165 | Mechanisms governing metastatic dormancy in breast cancer. | Semin Cancer Biol | 2017 | https://conductscience.org/library/papers/28344165 | PubMed |
| 10 | 30205045 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30205045 | PubMed |
| 11 | 28059068 | CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. | Nat Commun | 2017 | https://conductscience.org/library/papers/28059068 | PubMed |
| 12 | 10787412 | Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. | J Biol Chem | 2000 | https://conductscience.org/library/papers/10787412 | PubMed |
| 13 | 12736255 | Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12736255 | PubMed |
| 14 | 32300189 | The force awakens: metastatic dormant cancer cells. | Exp Mol Med | 2020 | https://conductscience.org/library/papers/32300189 | PubMed |
| 15 | 32541838 | Senescence as a therapeutically relevant response to CDK4/6 inhibitors. | Oncogene | 2020 | https://conductscience.org/library/papers/32541838 | PubMed |
| 16 | 2063198 | A corticosteroid receptor in neuronal membranes. | Science | 1991 | https://conductscience.org/library/papers/2063198 | PubMed |
| 17 | 20371346 | A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. | Cell | 2010 | https://conductscience.org/library/papers/20371346 | PubMed |
| 18 | 31318440 | ESR1 mutations in breast cancer. | Cancer | 2019 | https://conductscience.org/library/papers/31318440 | PubMed |
| 19 | 28027327 | Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. | PLoS Med | 2016 | https://conductscience.org/library/papers/28027327 | PubMed |
| 20 | 29555874 | Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors. | Cancer Res | 2018 | https://conductscience.org/library/papers/29555874 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41677624 | Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. | Cells | 2026 | https://conductscience.org/library/papers/41677624 | PubMed |
| 41444499 | LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells. | Sci Rep | 2025 | https://conductscience.org/library/papers/41444499 | PubMed |
| 39917165 | Interactions between key genes and pathways in prostate cancer progression and therapy resistance. | Front Oncol | 2025 | https://conductscience.org/library/papers/39917165 | PubMed |
| 38084101 | Genome-wide CRISPR/Cas9 screening for drug resistance in tumors. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38084101 | PubMed |
| 37035239 | CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/37035239 | PubMed |
| 35800743 | Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis. | Gland Surg | 2022 | https://conductscience.org/library/papers/35800743 | PubMed |
Genes24
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34944934
GET https://conductscience.org/api/papers/v1/34944934/references?page=2